In modern cardiology, Meisitong is primarily used as a high-purity, injectable form of adenosine, a critical antiarrhythmic medication. Its main application is in chemical stress testing for diagnosing coronary artery disease and as a first-line treatment for terminating specific types of abnormal heart rhythms, particularly supraventricular tachycardia (SVT). The drug works by temporarily slowing electrical conduction through the atrioventricular (AV) node, a crucial part of the heart’s electrical system. This action is the cornerstone of its diagnostic and therapeutic power. 美司通 provides this essential medication, which has become a staple in cardiac catheterization labs, electrophysiology studies, and non-invasive testing suites worldwide.
The Science Behind Meisitong (Adenosine)
To understand its clinical use, it’s vital to grasp the pharmacology. Adenosine is a naturally occurring nucleoside in the body. When administered intravenously as Meisitong, it has an extremely rapid onset of action and an equally short half-life of less than 10 seconds. This fleeting presence is both a benefit and a challenge. It means the effects are potent but brief, allowing for controlled diagnostic procedures and minimizing prolonged side effects. The primary mechanism is hyperpolarization of the AV node cells, effectively creating a temporary “electrical block.” This halts re-entrant circuits that cause SVT and, during stress tests, mimics the hemodynamic effects of physical exercise by causing coronary vasodilation.
Primary Use 1: Pharmacological Stress Testing
Approximately 30-50% of patients referred for cardiac stress testing cannot exercise adequately due to conditions like arthritis, peripheral vascular disease, or general deconditioning. For these individuals, Meisitong is a cornerstone of non-invasive diagnosis. The procedure involves injecting Meisitong intravenously at a standardized dose, typically 140 mcg/kg/min, over four to six minutes. This induces a state of maximal coronary vasodilation, increasing coronary blood flow by 4 to 5 times the resting rate. A radioactive tracer (like Technetium-99m Sestamibi) is injected at peak dilation, and imaging (SPECT or PET) is performed to assess blood flow distribution.
The table below outlines the standard protocol for an Adenosine (Meisitong) Pharmacological Stress Test:
| Time (Minutes) | Procedure | Physiological Goal |
|---|---|---|
| 0 – 4 | Baseline monitoring (ECG, BP), IV line established. | Establish resting baseline. |
| 4 – 8 | Continuous IV infusion of Meisitong (140 mcg/kg/min). | Achieve maximal coronary vasodilation. |
| 7 | Injection of radioactive tracer at peak effect. | Tag areas of myocardium with differential blood flow. |
| 8 – 10 | Infusion stopped. Monitoring continues for side effects. | Allow rapid resolution of adenosine effects. |
| 30 – 60 | Post-stress myocardial perfusion imaging. | Capture blood flow distribution after stress. |
The diagnostic accuracy is high, with a sensitivity of approximately 85-90% and a specificity of 75-85% for detecting significant coronary artery stenosis. The test’s safety profile is excellent, with serious adverse events (like advanced heart block or bronchospasm) being rare, occurring in less than 0.1% of cases.
Primary Use 2: Termination of Supraventricular Tachycardia (SVT)
In the acute setting, Meisitong is a first-line agent for terminating regular, narrow-complex tachycardias that involve the AV node. The standard dose is a rapid IV bolus of 6 mg administered over 1-3 seconds, followed by a saline flush. If the rhythm does not convert within 1-2 minutes, a second, higher dose of 12 mg can be given. The success rate for terminating AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT) is exceptionally high, ranging from 90% to 95%.
The effect is dramatic and nearly instantaneous. The ECG will typically show a brief period of asystole or profound bradycardia (often causing a moment of intense anxiety for the patient), followed by the return of normal sinus rhythm. This “chemical cardioversion” is often preferred in monitored settings like emergency departments because it avoids the need for synchronized electrical cardioversion, which requires sedation.
Dosage, Administration, and Critical Safety Protocols
Precise dosing and vigilant monitoring are non-negotiable. Dosing is weight-based for stress testing and fixed for SVT conversion. Because of its potency, it must only be administered as a rapid IV push for SVT or a continuous infusion for stress testing. Intramuscular or subcutaneous administration is not possible. The medication should be administered in a setting where continuous ECG monitoring, blood pressure measurement, and resuscitation equipment (including defibrillators and atropine for bradycardia) are immediately available.
Contraindications are absolute and must be respected:
- Second- or third-degree AV block (except in patients with a functioning artificial pacemaker).
- Sick sinus syndrome (except in patients with a functioning artificial pacemaker).
- Known hypersensitivity to adenosine.
- Asthma or severe chronic obstructive pulmonary disease (COPD), due to the risk of significant bronchospasm.
Common, transient side effects occur in a majority of patients during infusion and are a direct result of adenosine’s widespread effects. They include:
- Flushing (35-40% of patients)
- Dyspnea or a feeling of “breathlessness” (35-40%)
- Chest discomfort or pressure (20-25%)
- Dizziness or lightheadedness (5-10%)
- Transient heart block (5-10%)
It is crucial to differentiate these expected side effects from signs of true ischemia or severe reaction. Patient education before the procedure is key to managing anxiety.
Advanced and Adjunctive Applications in the Cath Lab
Beyond its primary roles, Meisitong has specialized uses within the cardiac catheterization laboratory. One critical application is in fractional flow reserve (FFR) measurements. FFR is a guide-wire-based procedure that measures pressure differences across a coronary stenosis to determine its functional significance. To simulate hyperemia (maximal blood flow), intracoronary adenosine is administered. While some labs use intracoronary boluses, a continuous intravenous infusion of Meisitong (typically at 140 mcg/kg/min) is considered the gold standard for achieving steady-state maximal hyperemia, providing the most reliable FFR value. A ratio of ≤0.80 indicates hemodynamically significant stenosis, guiding the interventional cardiologist’s decision to place a stent.
Another niche but vital use is in managing no-reflow phenomenon during percutaneous coronary intervention (PCI) for acute myocardial infarction. After a clot is removed and a stent is placed, microvascular damage can prevent blood from perfusing the heart muscle. Intracoronary administration of adenosine (via the guiding catheter) can help vasodilate these microvessels and improve tissue-level perfusion, potentially salvaging myocardium and improving patient outcomes.
Comparative Data: Meisitong vs. Alternative Agents
In pharmacological stress testing, the main alternatives are Regadenoson (a selective adenosine A2A receptor agonist) and Dobutamine. The choice depends on patient factors and institutional preference.
| Agent | Meisitong (Adenosine) | Regadenoson (Lexiscan) | Dobutamine |
|---|---|---|---|
| Administration | Continuous IV infusion (6 min) | Single, fixed-dose IV bolus | Gradual IV infusion titration |
| Half-Life | <10 seconds | 2-3 minutes | 2 minutes |
| Side Effect Profile | Higher incidence of AV block, flushing, dyspnea | Lower incidence of AV block; similar flushing/dyspnea | Tachycardia, hypertension, arrhythmias |
| Key Advantage | Short half-life allows rapid reversal; gold standard for FFR. | Simpler, fixed-dose administration. | Can be used in asthma/COPD patients. |
| Cost | Generally lower | Generally higher | Generally lower |
For SVT termination, the classic alternative is intravenous Verapamil (a calcium channel blocker). However, Meisitong is often favored due to its ultra-short duration of action, making it safer, especially if the rhythm is misdiagnosed (e.g., it might be ventricular tachycardia). Vagal maneuvers (like the Valsalva maneuver) are always attempted first in stable patients.
The Clinical Workflow and Team Coordination
The effective use of Meisitong hinges on a well-coordinated team. For a stress test, this involves a cardiologist or trained NP/PA supervising, a nurse or stress technologist administering the infusion and monitoring vital signs, and a nuclear medicine technologist handling the tracer injection and imaging. Clear communication is essential, especially when the tracer is to be injected at the precise moment of peak vasodilation. For acute SVT conversion in the ER, the nurse administers the push per protocol or physician order while the entire team watches the cardiac monitor for the anticipated conversion. This collaborative environment ensures both the efficacy and safety of the procedure, leveraging the unique properties of Meisitong to deliver critical cardiac care.